Evopoint Biosciences Co LtdSSE: 688837

(688837)"EVOPOINT BIOSCIENCES CO., LTD."Report for Q3 2026

Oct 29, 2026 · Issued by Evopoint Biosciences Co Ltd via Shanghai Stock Exchange

Filed with SSE · Stock code 688837 · Oct 29, 2026

On 6ix: 6ix.com/news/688837evopoint-biosciences-co-ltdreport-for-q3-2026

Report for Q3 2026

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix is reading this filing.

View original source (Shanghai Stock Exchange)Evopoint Biosciences Co Ltd on 6ix

Earlier from Evopoint Biosciences

(688837)"EVOPOINT BIOSCIENCES CO., LTD."Announcement on Opening of Dedicated Settlement Accounts for Cash Management Products Purchased with Raised FundsOct 21
(688837)"EVOPOINT BIOSCIENCES CO., LTD."Announcement on Approval by the National Medical Products Administration of the Clinical Trial Application for XNW26018 TabletsOct 21
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026Oct 10
Announcement on Resolutions of the 17th Meeting of the 2nd Board of DirectorsSep 24

All Evopoint Biosciences news releases

Follow Evopoint Biosciences into a list and get an email when it puts out news.

Follow Evopoint Biosciences